Trial completion date • Pan tumor
|
STK11 (Serine/threonine kinase 11) • NF1 (Neurofibromin 1) • KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
STK11 mutation • KEAP1 mutation • NFE2L2 mutation
|
telaglenastat (CB-839)